Impact of early weaning on constituents and nutritional values of camel milk in modern system.

Background: Camel milk is very suitable for human nutritional requirements, and its composition has similarities to mother's milk. Many scientific researches focusing on the myth of nutritional and therapeutic properties of camel milk have been brought to public attention. Aim: This study aims to clarify the impact of early weaning on constituents and nutritional values of the milk of camels reared under a modern farming system during four months postpartum. Methods: Eight lactating camels and eight calves were selected immediately after calving and were assigned to two equal groups under a semi-intensive system in a farm. In the early weaning group (G1), all the calves were allowed to freely suckle their mother's teats from birth to 30 days postpartum. Afterward, the calves were used to stimulate milk letdown for each of the camels' teats for a few seconds before the milking procedure. While in the late weaning group (G2), the calves freely suckled their mother's teats up to 80 days postpartum. Afterward, the calves were restricted from suckling and were used mainly to stimulate milk letdown for the milking procedure. Collection of milk samples started in the 2nd week of postpartum and continued over biweekly intervals up to 16 weeks to determine major fat, protein, lactose, solid non-fat (SNF), and density percentages. Results: The results revealed significant differences in fat, lactose, and density content between groups. We reported significant increases in the percentages of fat, lactose, protein, and SNF levels, besides fluctuations in density with the advancement of the lactation stage. Conclusion: In the early weaning group, the dams produced milk containing high levels of fat and SNF compared to the lactating dams in the late weaning group.

Diclofenac potassium liquid-filled soft gelatin capsules for the treatment of postbunionectomy pain.

OBJECTIVE: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) is a rapidly absorbed formulation of diclofenac approved for the treatment of mild to moderate acute pain in adults (≥18 years of age). The objective of this study was to investigate the efficacy and safety of DPSGC 25 mg in a multicenter, randomized, double-blind, placebo-controlled study in patients experiencing pain following first metatarsal bunionectomy. RESEARCH DESIGN AND METHODS: Patients experiencing a requisite level of pain (≥4 based on an 11-point numeric pain rating scale [NPRS]; 0 = no pain, 10 = worst pain possible) on the day following surgery were randomized to receive DPSGC 25 mg or placebo. Patients received a second dose (remedication) on request or at 8 hours postdose followed by additional doses every 6 hours through the end of postsurgery Day 4. Rescue medication (hydrocodone/acetaminophen) was available as needed after the second dose. CLINICAL TRIAL REGISTRATION: NCT00375934. MAIN OUTCOME MEASURE: The primary efficacy endpoint was the average NPRS score over the 48 hour inpatient multiple-dose period. RESULTS: DPSGC provided a significant improvement in mean 48 hour NPRS scores over placebo (3.29 vs 5.74, respectively; p < 0.0001), as well as for summed pain intensity difference (203.1 vs 86.6; p < 0.0001). Patients treated with DPSGC experienced a faster onset of meaningful pain relief compared with placebo (p = 0.0034). Rescue medication use on Day 1 and Day 2 was reduced in the DPSGC group compared with placebo (53.5% vs 92.1% on Day 1; 30.3% vs 67.3% on Day 2; p < 0.0001). DPSGC was well tolerated and no patients treated with DPSGC reported serious adverse events. As with any study, there are potential limitations including study design and patient population. CONCLUSION: These results indicate that DPSGC reduced pain in patients who underwent bunionectomy and this novel formulation of diclofenac potassium may be a practical option for treating mild to moderate acute pain.